Current Cardiovascular Risk Reports

, Volume 7, Issue 6, pp 490–494 | Cite as

Diabetic Cardiomyopathy in the Elderly

Elderly and Heart Disease (J Wei and G Azhar, Section Editors)


Diabetic cardiomyopathy is a microvascular disorder that occurs in diabetics that may lead to congestive heart failure (CHF) in the absence of hypertension, coronary artery disease, or valvular heart disease. In a large study of elderly subjects with 865 men and 1872 women, mean age 81 ± 9 years, CHF developed in 272 of 690 diabetics (39 %) and in 467 of 2047 nondiabetics (23 %) (P < 0.0001) at 43-month follow-up. Cox regression analysis showed that diabetes mellitus (risk ratio = 1.34, P = 0.0003) was an independent significant predictor of time to development of CHF. For each 1 % increase in hemoglobin A1c, in 25,958 men and 22,900 women with diabetes, there was an 8 % increased risk of CHF (95 % CI, 5 %–12 %). The pathologic substrate of diabetic cardiomyopathy is characterized by myocardial damage, left ventricular hypertrophy, interstitial fibrosis, structural and functional changes of the coronary vessels, metabolic abnormalities, and autonomic cardiac neuropathy.


Diabetic cardiomyopathy Heart failure Hyperglycemia Dyslipidemia Left ventricular hypertrophy Ejection fraction Diastolic dysfunction 


Compliance with Ethics Guidelines

Conflict of Interest

Wilbert S. Aronow declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kannel WB, Hjortland MC, Castelli WP. Role of diabetes in congestive heart failure. The Framingham Study. Am J Cardiol. 1974;34:29–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Aronow WS, Ahn C. Incidence of heart failure in 2737 older persons with and without diabetes mellitus. Chest. 1999;115:867–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function. The Strong Heart Study. Circulation. 2000;101:2271–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee M, Gardin JM, Lynch JC, et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the Cardiovascular Health Study. Am Heart J. 1997;133:36–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Boyer JK, Thanigaraj S, Schectman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic patients with diabetes mellitus. Am J Cardiol. 2004;93:395–9.CrossRefGoogle Scholar
  8. 8.
    Kosmala W, Kucharski W, Przewlocka-Kosmala M, Mazurek W. Comparison of left ventricular function by tissue Doppler imaging in patients with diabetes mellitus without systemic hypertension vs diabetes mellitus with systemic hypertension. Am J Cardiol. 2004;94:395–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Di Stante B, Galandauer I, Aronow WS, et al. Prevalence of left ventricular diastolic function in obese persons with and without diabetes mellitus. Am J Cardiol. 2005;95:1527–8.PubMedCrossRefGoogle Scholar
  10. 10.
    dei Cas L, Zuliani U, Maca C, et al. Non-invasive evaluation of left ventricular performance in 294 diabetic patients without clinical heart disease. Acta Diabetol Lat. 1980;17:145–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Popirier P, Garneau C, Bogaty P, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001;24:5–10.CrossRefGoogle Scholar
  12. 12.
    Karvounis HI, Papadopoulos CE, Zaglavara TA, et al. Evidence of left ventricular dysfunction in asymptomatic elderly patients with non-insulin-dependent diabetes mellitus. Angiology. 2004;55:549–55.PubMedCrossRefGoogle Scholar
  13. 13.
    Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–73.PubMedCrossRefGoogle Scholar
  14. 14.
    von Bibra H, Hansen A, Dounis V, et al. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart. 2004;90:1483–4.CrossRefGoogle Scholar
  15. 15.
    •• Markus MR, Stritzke J, Wellmann J, et al. Implications of prevalent and incident diabetes mellitus on left ventricular geometry and function in the ageing heart: the MONICA/KORA Augsburg cohort study. Nutr Metab Cardiovasc Dis. 2011;21:189–96. Over a 10-year follow-up period long-standing diabetes was associated with accelerated increase in left ventricular mass and left ventricular end-diastolic diameter and a reduction in left ventricular ejection fraction. Long-standing diabetes and incident diabetes which developed during the follow-up period were both associated with worse left ventricular diastolic function.PubMedCrossRefGoogle Scholar
  16. 16.
    Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54:1524–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Stefanidis A, Bousboulas S, Kalafatis J, et al. Left ventricular anatomical and functional changes with ageing in type 2 diabetic adults. Eur J Echocardiogr. 2009;10:647–53.PubMedCrossRefGoogle Scholar
  18. 18.
    • Aboukhoudir F, Rekik S. Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach. Int J Cardiovasc Imaging. 2012;28:1329–39. In diabetics with a normal resting left ventricular ejection fraction and no coronary artery disease or coronary vasospasm, dobutamine infusion during dobutamine stress echocardiography induced a significant deterioration in left ventricular ejection fraction (15% mean reduction), which was largely reversed by tighter glycemic control and addition of perindopril to their usual treatment.PubMedCrossRefGoogle Scholar
  19. 19.
    Raey DC. Which left ventricular dysfunction is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type 1 diabetic patients. Diabetes Care. 1994;17:633–9.CrossRefGoogle Scholar
  20. 20.
    Margogato A, Gerundini P, Vicedomini G, et al. Abnormal cardiovascular response to exercise in young asymptomatic diabetic patients with retinopathy. Am Heart J. 1986;112:554–60.CrossRefGoogle Scholar
  21. 21.
    Mildenberger RR, Bar-Schiomo B, Druck MN, et al. Clinically unrecognized dysfunction in young diabetic patients. J Am Coll Cardiol. 1984;4:234–8.PubMedCrossRefGoogle Scholar
  22. 22.
    van Heerebeek L, Hamdani N, Handoko L, et al. Diastolic stiffness of the failing diabetic heart. Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43–51.PubMedCrossRefGoogle Scholar
  23. 23.
    Nozynski J, Zakliczynski M, Konecka-Mrowka D, et al. Advanced glycation end products in the development of ischemic and dilated cardiomyopathy in patients with diabetes mellitus type 2. Transplant Proc. 2009;41:99–104.PubMedCrossRefGoogle Scholar
  24. 24.
    • Bodiga VL, Eda SR, Bodiga A. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev. 2013; [Epub ahead of print]. Advanced glycation end products are generated intracellularly and extracellularly as a result of chronic hyperglycemia. After interaction with receptors for advanced glycation end products (RAGEs), events leading to vascular and myocardial damage occur including oxidative stress, increased inflammation, and increased extracellular matrix accumulation, which result in left ventricular systolic and diastolic dysfunction. Google Scholar
  25. 25.
    • Liu JW, Liu D, Cui KZ, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy. Biochem Biophys Commun. 2012;427:441–3. Diabetes-induced metabolites such as glucose, advanced glycation end products, protein kinase C, free fatty acid, oxidative stress, and other related factors are implicated in the pathophysiology of diabetic cardiomyopathy.CrossRefGoogle Scholar
  26. 26.
    Kuethe F, Sigusch HH, Bornstein SR, et al. Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy. Horm Metab Res. 2007;39:672–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Isfort M, Stevens SC, Schaffer S, et al. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev. 2013; [Epub ahead of print].Google Scholar
  28. 28.
    • Goyal B, Mehta A. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfunction. Hum Exp Toxicol. 2013;32:571–90. Myocardial fibrosis, small vessel disease, and cardiac autonomic neuropathy are major players in the pathophysiology of diabetic cardiomyopathy.PubMedCrossRefGoogle Scholar
  29. 29.
    •• Chavali V, Tyagi SC, Mishra PK. Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes. 2013;6:151–60. The 3 major stages of diabetic cardiomyopathy are; (1) an early stage with cellular and metabolic changes without clinical left ventricular systolic dysfunction; (2) the middle stage with increased apoptosis, an increase in left ventricular size, diastolic dysfunction, and an ejection fraction less than 50%; (3) the late stage with altered microvasculature compliance, increase in left ventricular size, and a reduction in cardiac performance leading to heart failure.PubMedGoogle Scholar
  30. 30.
    Yokoyama I, Ohrake T, Momoura S, et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes. 1998;47:119–24.PubMedCrossRefGoogle Scholar
  31. 31.
    Pikanen OP, Nuutila P, Raitakari S, et al. Coronary flow reserve in young men with IDDM. Diabetes. 1998;47:248–54.CrossRefGoogle Scholar
  32. 32.
    Fein FS, Sonnenblick EM. Diabetic cardiomyopathy. Prog Cardiovasc Dis. 1985;27:255–70.PubMedCrossRefGoogle Scholar
  33. 33.
    Blumenthal HT, Alex M, Goldenberg S. A study of lesions of the intramural coronary artery branches in diabetes mellitus. Arch Pathol. 1960;70:27.Google Scholar
  34. 34.
    Pearce MB, Bullock RT, Kissiar JC. Myocardial small-vessel disease in patients with diabetes mellitus. Circulation. 1973;48 Suppl 4:6.Google Scholar
  35. 35.
    Zoneraich S, Silverman G, Zoneraich O. Primary myocardial disease, diabetes mellitus and small-vessel disease. Am Heart J. 1980;5:754–5.CrossRefGoogle Scholar
  36. 36.
    Zoneraich S. Small-vessel disease, coronary artery vasodilator reserve, and diabetic cardiomyopathy. Chest. 1988;94:5–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci. 2004;107:539–57.PubMedCrossRefGoogle Scholar
  38. 38.
    Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impaired endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 1991;87:1643–8.PubMedCrossRefGoogle Scholar
  39. 39.
    •• Schilling JD, Mann DL. Diabetic cardiomyopathy. Bench to bedside. Heart Fail Clin. 2012;8:619–31. Cellular and molecular mechanisms leading to diabetic cardiomyopathy include hyperglycemia, dyslipidemia, oxidative stress, abnormal cardiac myocyte calcium handling, hyperactive protein kinase C signaling in the heart, apoptosis, inflammation, fibrosis, and mitochondrial dysfunction.PubMedCrossRefGoogle Scholar
  40. 40.
    •• Seferovic PM, Milinkovic I, Ristic AD, et al. Diabetic cardiomyopathy: ongoing controversies in 2012. Herz. 2012;37:880–6. The pathologic substrate of diabetic cardiomyopathy is myocardial damage, left ventricular hypertrophy, interstitial fibrosis, structural, and functional changes of the small coronary vessels, metabolic abnormality, and autonomic cardiac neuropathy. Hyperglycemia and insulin resistance with hyperinsulinemia and reduced insulin sensitivity contribute to the pathogenesis of cardiomyopathy.PubMedCrossRefGoogle Scholar
  41. 41.
    Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:1343–82.CrossRefGoogle Scholar
  42. 42.
    Kamalesh M. Heart failure in diabetes and related conditions. J Card Fail. 2007;13:861–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Cohen-Solal A, Beauvais F, Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail. 2008;14:615–25.PubMedCrossRefGoogle Scholar
  44. 44.
    •• American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11–66. The American Diabetes Association 2013 guidelines state that a reasonable hemoglobin A1c goal for diabetics is less than 7.0%. Systolic blood pressure in most diabetics with hypertension should be reduced to less than 140 mm Hg, with use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Serum low-density lipoprotein cholesterol should be reduced to less than 70 mg/dl with statins.CrossRefGoogle Scholar
  45. 45.
    Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–51.PubMedCrossRefGoogle Scholar
  46. 46.
    Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure. Diabetes Care. 2007;30:2148–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114.PubMedCrossRefGoogle Scholar
  48. 48.
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRefGoogle Scholar
  49. 49.
    Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.PubMedCrossRefGoogle Scholar
  50. 50.
    Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328:189.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Medicine, Divisions of Cardiology, Geriatrics, and Pulmonary/Critical CareNew York Medical CollegeValhallaUSA

Personalised recommendations